Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 alone or with Abiraterone or Enzalutamide in CRPC
NCT02034552Phase 2Completed
- Sponsor
- Bayer
- Start
- Mar 2014
- Primary completion
- Jul 2016
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of radium-223 dichloride in castration-resistant prostate cancer (CRPC) (3 arms), sponsored by Bayer. Primary endpoints: Patient Bone Scan Response Rate at 24 weeks and Bone Scan Lesion Area at 24 weeks. Started Mar 2014; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02034552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02034552.